Posted on Jun 12, 2014, 6 a.m.
A systematic review of research on Cannabidiol (CBD) shows evidence of CBD's anxiolytic effects in humans.
Evidence of cannabidiol’s (CBD) anxiolytic effects is been shown in an increasing number of studies. Cannabidiol (CBD), a major constituent of Cannabis sativa, is a good candidate for therapeutic applications because it has no psychoactive effect and does not impair cognition, unlike Tetrahydrocannabinol (THC) or the “high” typically associated with the use of marijuana.
In a thorough review of the scientific literature on the anxiolytic properties of CBD, a team of academic researchers from Brazil finds that recent studies “support the view that CBD has a vast array of possible therapeutic effects. Among these possibilities, the anxiolytic and antipsychotic properties of CBD stand out. CBD's anxiolytic effects are apparently similar to those of approved drugs to treat anxiety.”
Today’s research about the effect of cannabidiol is paving the way to promising therapeutic and pharmacological applications of CBD to affect anxiety disorders, including social anxiety disorder, post-traumatic stress disorders, and panic disorder. The authors of the review conclude that “CBD appears to be the cannabinoid compound that is closer to have its preliminary findings in anxiety translated into clinical practice.”
Schier, Alexandre Rafael de Mello, Ribeiro, Natalia Pinho de Oliveira, Silva, Adriana Cardoso de Oliveira e, Hallak, Jaime Eduardo Cecílio, Crippa, Jos e Alexandre S., Nardi, Antonio E., & Zuardi, Antonio Waldo. (2012). Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Revista Brasileira de Psiquiatria, 34(Suppl. 1), 104110. Retrieved May 28, 2014, from http://www.scielo.br/scielo.php?script=sci_arttext&pid=S151644462012000500008&lng=en&tlng=en. 10.1590/S151644462012000500008.
News Abstract furnished by HempMeds PX